logo
Twitter
Discord
Email
logo
Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

NASDAQ•ARQT
CEO: Mr. Todd Franklin Watanabe M.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-01-31
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Contact Information
3027 Townsgate Road, Suite 300, Westlake Village, CA, 91361, United States
805-418-5006
www.arcutis.com
Market Cap
$3.17B
P/E (TTM)
-74.4
38.2
Dividend Yield
--
52W High
$31.77
52W Low
$11.13
52W Range
71%
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025

Financial Dashboard

Q3 2025 Data

Revenue

$99.22M+121.69%
4-Quarter Trend

EPS

$0.06-118.18%
4-Quarter Trend

FCF

-$1.75M-94.96%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Q3 Profitability Achieved Net income $7.41M USD for the quarter, reversing $41.54M USD loss reported in Q3 2024.
Product Revenue Growth Strong Nine-month product revenue reached $244.57M USD, showing 152% growth over the comparable prior period.
ZORYVE 0.15% Sales Explode ZORYVE cream 0.15% product revenue grew 1686% YTD to $43.78M USD following US launch.
R&D Expenses Decreased Nine-month R&D expenses fell 9% to $56.60M USD due to completion of certain clinical studies.

Risk Factors

Accumulated Deficit High Accumulated deficit reached $1.156B USD as of September 30, 2025, indicating ongoing operational burn.
Lease Liability Increased Lease amendment increased operating lease liability by $2.9M USD in Q3 2025 due to term extension.
Tax Law Uncertainty Poses Risk Potential US federal tax law changes, like the One Big Beautiful Bill Act, pose operational risks.
Reliance on Single Suppliers Reliance on single-source suppliers for manufacturing and clinical trial materials creates supply chain risk.

Outlook

ARQ-234 Phase 1 Study Anticipate commencing Phase 1 study for ARQ-234 in atopic dermatitis during the first quarter of 2026.
ZORYVE Label Expansion Focus Expect continued R&D spend for ZORYVE label expansions and life cycle management moving forward.
Liquidity Sufficient Twelve Months Management believes existing capital resources cover projected operating requirements for at least 12 months.
SGA Expenses Expected Increase Selling, general, and administrative expenses expected to increase due to commercialization efforts for ZORYVE.

Peer Comparison

Revenue (TTM)

Amicus Therapeutics, Inc.FOLD
$598.70M
+21.3%
Catalyst Pharmaceuticals, Inc.CPRX
$578.20M
+25.6%
Travere Therapeutics, Inc.TVTX
$435.83M
+114.2%

Gross Margin (Latest Quarter)

IDEAYA Biosciences, Inc.IDYA
99.5%
+0.0pp
Travere Therapeutics, Inc.TVTX
99.0%
+54.4pp
Arcutis Biotherapeutics, Inc.ARQT
91.2%
+3.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IBRX$5.44B-15.062.8%0.0%
FOLD$4.43B-314.4-6.8%51.0%
BEAM$3.17B-7.7-42.9%11.5%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
11.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:$0.02
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 28, 2025|
    Revenue: $99.22M+121.7%
    |
    EPS: $0.06-118.2%
    Beat

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $81.50M+164.1%
    |
    EPS: $-0.13-69.0%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $65.85M+32.8%
    |
    EPS: $-0.20-37.5%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|
    Revenue: $196.54M+229.7%
    |
    EPS: $-1.16+69.3%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $44.76M+17.4%
    |
    EPS: $-0.33-54.8%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $30.86M+494.6%
    |
    EPS: $-0.42-63.8%
    Beat

  • Form 10-Q/A - Q1 2024

    Period End: Mar 31, 2024|Filed: Jul 24, 2024|
    Revenue: $49.57M+1682.4%
    |
    EPS: $-0.32-75.4%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|Refer to amended data